Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.

abstract：:Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Phillips P,Rotstein C,Puodziunas A,Shafran S,Garber G,Smaill F,Salit I,Miller M,Williams K,Conly J,Singer J,Ioannou S

更新日期：1998-05-01 00:00:00

abstract：BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...

journal_title：PharmacoEconomics

authors： Najafzadeh M,Garces JA,Maciel A

更新日期：2017-12-01 00:00:00

abstract：:This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

journal_title：PharmacoEconomics

authors： Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

更新日期：1997-04-01 00:00:00

abstract：BACKGROUND:National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices regarding how to model values from the coll...

journal_title：PharmacoEconomics

authors： Augestad LA,Rand-Hendriksen K,Kristiansen IS,Stavem K

更新日期：2012-12-01 00:00:00

abstract：:This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Drummond MF

更新日期：1994-05-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：:About one-quarter of men aged 50 years and older experience voiding problems due to benign prostatic hyperplasia (BPH). Until about 10 years ago, surgery (particularly transurethral resection of the prostate) was the only effective treatment for symptomatic BPH. Over the last decade, several new treatments have been i...

journal_title：PharmacoEconomics

authors： Stoevelaar HJ,McDonnell J

更新日期：2001-01-01 00:00:00

abstract：:An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

journal_title：PharmacoEconomics

authors： Gerbrandt KR,Yedinak KC

更新日期：1996-12-01 00:00:00

abstract：:Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indic...

journal_title：PharmacoEconomics

authors： Mistry H,Nduka C,Connock M,Colquitt J,Mantopoulos T,Loveman E,Walewska R,Mason J

更新日期：2018-04-01 00:00:00

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：:Diseases of the prostate currently represent a major health problem worldwide. As the age of the male population increases in the future, so will the number of patients suffering from these disorders and the cost for treatment increase. Currently, benign prostatic hyperplasia (BPH) and prostate cancer are common in ...

journal_title：PharmacoEconomics

authors： Amin EA,Amin M

更新日期：1992-05-01 00:00:00

abstract：BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...

journal_title：PharmacoEconomics

authors： Laba TL,Reddel HK,Zwar NJ,Marks GB,Roughead E,Flynn A,Goldman M,Heaney A,Lembke K,Jan S

更新日期：2019-02-01 00:00:00

abstract：:Cefotaxime is a parenterally administered third generation cephalosporin with a broad spectrum of antimicrobial activity. After more than a decade of use, cefotaxime continues to play an important role in the treatment of patients with serious infections, particularly those caused by Gram-negative bacteria. Clinical t...

journal_title：PharmacoEconomics

authors： Plosker GL,Foster RH,Benfield P

更新日期：1998-01-01 00:00:00

abstract：INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

journal_title：PharmacoEconomics

authors： Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use p...

journal_title：PharmacoEconomics

authors： Degrassat-Théas A,Paubel P,Parent de Curzon O,Le Pen C,Sinègre M

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Terkola R,Overton PM,Shalet N,Postma M

更新日期：2017-08-01 00:00:00

abstract：:There is an inevitable tension between robust reimbursement processes and providing speedy access to new and novel technologies, given uncertainties about key pieces of evidence and subsequent concerns regarding their overall efficiency. The public perception of these treatments as 'breakthrough', combined with substa...

journal_title：PharmacoEconomics

authors： McCabe CJ,Stafinski T,Edlin R,Menon D,Banff AED Summit.

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the...

journal_title：PharmacoEconomics

authors： Schmitz S,Makovski TT,Adams R,van den Akker M,Stranges S,Zeegers MP

更新日期：2020-01-01 00:00:00

abstract：:Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

journal_title：PharmacoEconomics

authors： Yang BM

更新日期：2009-01-01 00:00:00

abstract：:A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

journal_title：PharmacoEconomics

authors： Oremus M,Aguilar SC

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral). We conducted a cost evaluati...

journal_title：PharmacoEconomics

authors： Hasegawa T,Imai H,Miki S

更新日期：2003-01-01 00:00:00

abstract：:The efficacy of granisetron in preventing acute nausea and vomiting during the 24 hours following chemotherapy in patients with cancer is equivalent to that of other serotonin 5-HT3 receptor antagonists (ondansetron and tropisetron) and similar to or greater than that of conventional antiemetic regimens such as metocl...

journal_title：PharmacoEconomics

authors： Plosker GL,Benfield P

更新日期：1996-04-01 00:00:00

abstract：:The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...

journal_title：PharmacoEconomics

authors： Dahlöf C,Bouchard J,Cortelli P,Heywood J,Jansen JP,Pham S,Hirsch J,Adams J,Miller DW

更新日期：1997-01-01 00:00:00

abstract：OBJECTIVES:Patients with chronic kidney disease (CKD) are commonly treated with renin-angiotensin-aldosterone system inhibitors (RAASi) in order to delay progression of renal disease. However, research has shown that RAASi in CKD patients increases hyperkalaemia (HK) prevalence, which leads to RAASi discontinuation or ...

journal_title：PharmacoEconomics

authors： Widén J,Ivarsson M,Schalin L,Vrouchou P,Schwenkglenks M,Heimbürger O,Ademi Z,Sutherland CS

更新日期：2020-07-01 00:00:00

abstract：:In this article, we model the behavior of a pharmaceutical firm that has marketing authorization for a new therapy believed to be a candidate for personalized use in a subset of patients, but that lacks information as to why a response is seen only in some patients. We characterize the optimal outcome-based reimbursem...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2018-07-01 00:00:00

abstract：:Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

journal_title：PharmacoEconomics

authors： Naci H,Fleurence R,Birt J,Duhig A

更新日期：2010-01-01 00:00:00

abstract：:A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is pro...

journal_title：PharmacoEconomics

authors： Watkins K,Connell CM

更新日期：2004-01-01 00:00:00

abstract：:This tutorial presents practical guidance on transforming various types of information published in journals, or available online from government and other sources, into transition probabilities for use in state-transition models, including cost-effectiveness models. Much, but not all, of the guidance has been previou...

journal_title：PharmacoEconomics

authors： Gidwani R,Russell LB

更新日期：2020-11-01 00:00:00

abstract：:This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

journal_title：PharmacoEconomics

authors： Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

更新日期：1997-09-01 00:00:00

abstract：:Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies,...

journal_title：PharmacoEconomics

authors： Nuijten MJ

更新日期：2004-01-01 00:00:00